Thomas B. Farb
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Pancreatic function and diabetes, Diabetes Treatment and Management, Diet, Metabolism, and Disease, Cannabis and Cannabinoid Research, Neuroendocrine Tumor Research Advances
Most-Cited Works
- → Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets(2010)139 cited
- → Regulation of GPR119 receptor activity with endocannabinoid-like lipids(2012)118 cited
- → BACH2 inhibition reverses β cell failure in type 2 diabetes models(2021)68 cited
- → Small Molecule Allosteric Modulation of the Glucagon-Like Peptide-1 Receptor Enhances the Insulinotropic Effect of Oxyntomodulin(2012)54 cited
- → Inhibition of Deoxyhypusine Synthase Enhances Islet β Cell Function and Survival in the Setting of Endoplasmic Reticulum Stress and Type 2 Diabetes(2010)45 cited
- → Ectonucleotidase NTPDase3 is abundant in pancreatic β-cells and regulates glucose-induced insulin secretion(2013)44 cited
- → Episodic β‐cell death and dedifferentiation during diet‐induced obesity and dysglycemia in male mice(2018)42 cited
- → Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R-dependent manner(2021)33 cited
- → Characterization of a novel polyclonal anti-hypusine antibody(2013)32 cited
- → Thioredoxin-mimetic peptides (TXM) inhibit inflammatory pathways associated with high-glucose and oxidative stress(2016)28 cited